Echelon Wealth Partners Sticks to Its Buy Rating for Invesque (MHIVF)

Echelon Wealth Partners analyst Stephan Boire maintained a Buy rating on Invesque (MHIVFResearch Report) on November 15 and set a price target of $9.25. The company’s shares closed last Monday at $6.87.

Boire has an average return of 13.2% when recommending Invesque.

According to TipRanks.com, Boire is ranked #2977 out of 5679 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Invesque with a $7.39 average price target, representing a 6.5% upside. In a report issued on November 15, CIBC also maintained a Buy rating on the stock with a C$7.50 price target.

See today’s analyst top recommended stocks >>

Based on Invesque’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.9 million. In comparison, last year the company had a net profit of $8.65 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Invesque, Inc. is a real estate investment company, which engages in the acquisition of health care and senior living properties. Its portfolio includes investment properties which are operated by providers of transitional care, long-term care, independent living, assisted living and medical office properties.